iShares MSCI Germany (DAX) vs Viatris Inc — how do they compare? iShares MSCI Germany (DAX) trades at $43.82, while Viatris Inc trades at $16.26 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals.
| EWG | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $17.86 |
52-Week Low | $38.08 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
EWG trades at $44.04, up 0.39% today, with a bullish technical signal driven by moving averages. Key support and resistance cluster at $44. Recent news highlights European Central Bank rate decisions and German economic policies influencing regional markets.
The outlook is cautiously optimistic given technical strength, but fundamental data is unavailable. Risks include European economic volatility and energy price fluctuations. Investors should assess upcoming financial disclosures for valuation clarity.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Trailing returns across standard periods
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →